Twist Bioscience insider plans sale of 3,500 shares

Patrick Finn filed a notice to sell up to 3,500 shares of Twist Bioscience common stock under Rule 144.

Rhea-AI Filing Summary

Patrick Finn filed a notice to sell up to 3,500 shares of Twist Bioscience common stock under Rule 144. The filing lists an aggregate market value of 175,789.00 for these shares, to be sold through Fidelity Brokerage Services LLC on NASDAQ.

The shares come from option grants dated 11/19/2018 and 10/24/2019 totaling 2,500 shares, and 1,000 shares from restricted stock vesting on 11/08/2024. Recent activity also shows separate sales, including 23,279 shares on 01/13/2026 for gross proceeds of 931,160.00.

Insights

Equity capital markets analyst

Routine Rule 144 filing for planned insider share sales.

The notice shows Patrick Finn planning to sell up to 3,500 shares of Twist Bioscience common stock under Rule 144, with an aggregate market value of 175,789.00. The shares come from option exercises and restricted stock vesting, which are common sources of insider liquidity.

The document also details several prior sales in the last three months, including 23,279 shares sold on 01/13/2026 for gross proceeds of 931,160.00. This pattern suggests ongoing diversification rather than a discrete corporate event. Overall, this appears to be a standard insider selling program rather than a thesis-changing development.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing for TWST’s Patrick Finn disclose?

The filing discloses that Patrick Finn plans to sell up to 3,500 shares of Twist Bioscience common stock. The shares have an aggregate market value of 175,789.00 and will be sold on NASDAQ through Fidelity Brokerage Services LLC under Rule 144.

How many Twist Bioscience (TWST) shares is Patrick Finn planning to sell?

Patrick Finn’s notice covers up to 3,500 Twist Bioscience common shares. The filing states an aggregate market value of 175,789.00 for these shares, to be transacted through Fidelity Brokerage Services LLC on NASDAQ, subject to Rule 144 conditions and market execution.

What is the source of the TWST shares Patrick Finn plans to sell?

The shares come from option grants and restricted stock vesting. The filing lists 1,500 shares from an option granted 11/19/2018, 1,000 from an option granted 10/24/2019, and 1,000 from restricted stock that vested on 11/08/2024, totaling 3,500 shares.

What recent TWST share sales by Patrick Finn are reported in the filing?

The filing lists several recent sales, including 1,776 shares on 11/21/2025, 23,279 shares on 01/13/2026, 2,390 shares on 01/23/2026, and 2,705 shares on 02/03/2026. Gross proceeds range from 47,070.22 to 931,160.00, showing substantial recent selling activity.

On which exchange will the TWST shares in Patrick Finn’s Form 144 be sold?

The notice specifies that the 3,500 Twist Bioscience common shares are expected to be sold on NASDAQ. Fidelity Brokerage Services LLC is listed as the broker, and the filing associates an aggregate market value of 175,789.00 with the planned sales under Rule 144.

What representation does Patrick Finn make in the TWST Form 144 filing?

By signing the notice, Patrick Finn represents that he does not know any material adverse information about Twist Bioscience’s current or prospective operations that has not been publicly disclosed, as required in the standard Rule 144 form language for such planned sales.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/12/2026 - 05:00 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001755970
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Twist Bioscience Corp
SEC File Number	001-38720
Address of Issuer	681 GATEWAY BLVD. SOUTH SAN FRANCISCO CALIFORNIA 94080
Phone	800-719-0671
Name of Person for Whose Account the Securities are To Be Sold	Finn Patrick John
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	3500	175789.00	61311704	02/12/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	02/12/2026	Option Granted - 11/19/2018	Issuer			1500	02/12/2026	Cash
Common	02/12/2026	Option Granted - 10/24/2019	Issuer			1000	02/12/2026	Cash
Common	11/08/2024	Restricted Stock Vesting	Issuer			1000	11/08/2024	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Patrick Finn 681 Gateway Blvd South San Francisco CA 94080	Common	11/21/2025	1776	47070.22
Patrick Finn 681 Gateway Blvd South San Francisco CA 94080	Common	01/13/2026	23279	931160.00
Patrick Finn 681 Gateway Blvd South San Francisco CA 94080	Common	01/23/2026	2390	107329.41
Patrick Finn 681 Gateway Blvd South San Francisco CA 94080	Common	02/03/2026	2705	125986.73

144: Remarks and Signature

Remarks
Date of Notice	02/12/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	05/13/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Louis Kurnick, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Patrick Finn
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)